Our Science
![](https://www.nuvigtherapeutics.com/wp-content/uploads/fly-images/585/science-scaled-subhead-0x0.jpg)
Modulating Immune Function
Our bodies respond to inflammatory stimuli (like a pathogenic infection) with a protective inflammatory cascade. This inflammatory response is tightly regulated by molecular mechanisms involving circulating antibodies, which can re-establish homeostasis after an infection clears. Antibodies can be either pro-inflammatory or anti-inflammatory depending on a switch located on a specific part (Fc domain) of immunoglobulin G (IgG) antibodies. When antibodies are coated with a sugar group (sialylation), they can bind to Type II Fcγ receptors, which returns the immune environment to an anti-inflammatory (tolerant or vigilant) state.
Limitations of IVIg Immune Modulation
IVIg immune modulation is effective in treating autoimmune diseases, but is limited by supply & preparation as a blood product therapy with inherent safety risks and narrow therapeutic window.
![](https://www.nuvigtherapeutics.com/wp-content/uploads/fly-images/716/IVIg-funnel@2x-1-500x0.png)
![](https://www.nuvigtherapeutics.com/wp-content/uploads/fly-images/602/shield-525x0.png)
Limitations of Immunosuppression
Most autoimmune therapies suppress immune function, which can poke holes in the immune system's defense shield, presenting significant infection risks to patients.
NVG-2089
NVG-2089 triggers our bodies’ endogenous regulatory mechanisms to reduce autoimmune dysregulation without immunosuppression. NVG-2089 is designed to mimic the binding of sialylated IgG to immunomodulatory Type II Fcγ receptors. A Phase 1 clinical study demonstrated the safety and tolerability of NVG-2089 in healthy volunteers.
![](https://www.nuvigtherapeutics.com/wp-content/uploads/fly-images/603/nvg-2089-425x0.png)
Our Platform
At Nuvig, we incorporate our engineered Fc into full-length antibodies to create bi- and tri-functional antibodies. We call this BESTech™ (Biologic Enhancement of Self Tolerance).
In preclinical experiments we observed substantially enhanced efficacy with the combination of our BESTech Fc and an anti-cytokine variable region (e.g. together, a BESTech mAb) vs. the wild-type antibody. We believe BESTech can be applied to multiple anti-inflammatory targets.
See our therapeutic areas.